Aratana Therapeutics Company Profile (NASDAQ:PETX)

About Aratana Therapeutics

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PETX
  • CUSIP:
Key Metrics:
  • Previous Close: $9.36
  • 50 Day Moving Average: $7.93
  • 200 Day Moving Average: $6.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.36
  • P/E Growth: -0.83
  • Market Cap: $331.48M
  • Outstanding Shares: 35,415,000
  • Beta: 3.84
Additional Links:
Companies Related to Aratana Therapeutics:

Analyst Ratings

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $11.86 (26.68% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
DateFirmActionRatingPrice TargetDetails
8/19/2016Jefferies GroupInitiated CoverageBuy$12.00 -> $13.00View Rating Details
8/17/2016William BlairReiterated RatingOutperformView Rating Details
8/11/2016Barclays PLCLower Price TargetOverweight$15.00 -> $11.00View Rating Details
8/10/2016Credit Suisse Group AGReiterated RatingBuy$11.00View Rating Details
7/17/2016Lake Street CapitalReiterated RatingBuy$15.00View Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00View Rating Details
3/16/2016Stifel NicolausLower Price TargetBuy$12.00 -> $11.00View Rating Details
11/4/2015Piper Jaffray Cos.Reiterated RatingOverweight$25.00 -> $15.00View Rating Details
2/25/2015JMP SecuritiesSet Price TargetBuy$38.00View Rating Details
2/25/2015Bank of America Corp.Boost Price Target$26.00View Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Aratana Therapeutics (NASDAQ:PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)ViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
Current Year EPS Consensus Estimate: $-0.73 EPS
Next Year EPS Consensus Estimate: $-1.12 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.40)($0.41)
Q2 20162($0.43)($0.41)($0.42)
Q3 20163($0.43)($0.39)($0.41)
Q4 20162($0.40)($0.34)($0.37)
Q1 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
DateHeadline logoETF’s with exposure to Aratana Therapeutics, Inc. : August 25, 2016 (NASDAQ:PETX) - August 25 at 11:53 AM logoOctober 21st Options Now Available For Aratana Therapeutics (PETX) (NASDAQ:PETX) - August 23 at 11:12 AM logoAratana Therapeutics, Inc. (NASDAQ:PETX) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:PETX) - August 22 at 6:43 PM logoAratana Therapeutics : Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics (NASDAQ:PETX) - August 17 at 7:04 PM
News IconHome Biotech Stocks Aratana Therapeutics, Inc. | $PETX Stock | Shares Spike Up On FDA... - TickerTV News (press release) (NASDAQ:PETX) - August 17 at 9:49 AM
News IconAratana Therapeutics Granted FDA Approval of NOCITA (bupivacaine liposome injectable suspension) (NASDAQ:PETX) - August 16 at 6:56 PM logoWill Aratana Therapeutics, Inc. (NASDAQ:PETX) Hit $18 Price Target? - Investor Newswire (NASDAQ:PETX) - August 16 at 10:03 AM logoAratana Therapeutics (PETX) Announces FDA Approval of NOCITA - (NASDAQ:PETX) - August 16 at 10:03 AM logoAratana Therapeutics (PETX) Announces FDA Approval of NOCITA (NASDAQ:PETX) - August 15 at 7:08 PM logo4:34 pm Aratana Therapeutics granted FDA approval of NOCITA (NASDAQ:PETX) - August 15 at 7:08 PM logoAratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) (NASDAQ:PETX) - August 15 at 7:08 PM logoARATANA THERAPEUTICS, INC. Financials (NASDAQ:PETX) - August 13 at 6:27 PM logoETF’s with exposure to Aratana Therapeutics, Inc. : August 12, 2016 (NASDAQ:PETX) - August 12 at 6:56 PM logoAratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:PETX) - August 11 at 7:18 PM
News IconAratana Therapeutics Inc (NASDAQ:PETX): Power Of Breakout Alert , We Made 15% Profit In Swing Trading (NASDAQ:PETX) - August 10 at 9:53 AM
News IconHealthcare Companies in Hotspot: Aratana Therapeutics, Inc. (NASDAQ:PETX), Mast Therapeutics, Inc. (NYSEMKT ... - TWN (NASDAQ:PETX) - August 9 at 7:02 PM
News IconHC Stocks Vigilant: Mast Therapeutics Inc (NYSEMKT:MSTX ... - share market updates (press release) (NASDAQ:PETX) - August 8 at 7:00 PM logoCurrent Aratana Therapeutics, Inc. (NASDAQ:PETX) PT Means Stock Is Worth Almost $15 - Review Fortune (NASDAQ:PETX) - August 8 at 7:00 PM
News IconUnusual Healthcare Volume Gainers In Focus- Aratana Therapeutics (NASDAQ:PETX), Merck & Co (NYSE:MRK) - Seneca Globe (NASDAQ:PETX) - August 8 at 11:28 AM logoAnalyst Rating Fluctuations to Observe: Zoetis Inc. (NYSE:ZTS) , Aratana Therapeutics, Inc. (NASDAQ:PETX) - Street Updates (NASDAQ:PETX) - August 8 at 11:28 AM logoAratana Therapeutics (PETX) Worth a Look: Stock Gains 6.2% (NASDAQ:PETX) - August 8 at 11:28 AM logoAratana Therapeutics Inc. (PETX) Jumps 6.15% on August 05 - (NASDAQ:PETX) - August 6 at 9:35 AM logoEdited Transcript of PETX earnings conference call or presentation 5-Aug-16 12:30pm GMT (NASDAQ:PETX) - August 6 at 9:35 AM logoETF Preview: ETFs, Futures Jump Higher on Solid July Jobs Report (NASDAQ:PETX) - August 5 at 9:51 AM logoAratana beats Street 2Q forecasts (NASDAQ:PETX) - August 5 at 9:51 AM logoARATANA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:PETX) - August 5 at 9:51 AM logoARATANA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or (NASDAQ:PETX) - August 4 at 7:15 PM logoAratana Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:PETX) - August 4 at 7:15 PM logoDrug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More (NASDAQ:PETX) - August 4 at 9:56 AM logoQ2 2016 Aratana Therapeutics Inc Earnings Release - After Market Close (NASDAQ:PETX) - August 4 at 9:56 AM logoCan Shares Of Aratana Therapeutics, Inc. (NASDAQ:PETX) Hit $18? - Investor Newswire (NASDAQ:PETX) - July 26 at 7:07 PM logoAratana Therapeutics, Inc. (PETX) Updated Price Targets - FTSE News (NASDAQ:PETX) - July 26 at 7:07 PM logoETF’s with exposure to Aratana Therapeutics, Inc. : July 26, 2016 (NASDAQ:PETX) - July 26 at 12:55 PM logoCan Aratana Therapeutics, Inc. (NASDAQ:PETX) Surprise Analysts this Quarter? - Investor Newswire (NASDAQ:PETX) - July 24 at 10:56 AM logoAccounts Payable For Aratana Therapeutics, Inc. (NASDAQ:PETX) Stood At $6.38 - (NASDAQ:PETX) - July 23 at 6:18 PM logoAratana Therapeutics Inc (NASDAQ:PETX) Price Volatility Hits An Elevated Level - CML News (NASDAQ:PETX) - July 22 at 6:40 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Aratana Therapeutics, Inc. (NASDAQ:PETX) - TGP (NASDAQ:PETX) - July 21 at 7:06 PM
News IconStock Focus: Following Analyst Expectations on Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) - TGP (NASDAQ:PETX) - July 21 at 7:06 PM
News IconHeightened Volatility Spotted on Shares of: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Engelwood Daily (NASDAQ:PETX) - July 20 at 9:39 AM
News IconAwm Investment Company INC Increased Aratana Therapeutics INC (NASDAQ:PETX) by $3.76 Million as Shares Rose - Press Telegraph (NASDAQ:PETX) - July 19 at 6:55 AM logoNew Broker Ratings For Aratana Therapeutics, Inc. (PETX) - FTSE News (NASDAQ:PETX) - July 18 at 6:54 PM
News IconAratana Therapeutics Incorporated (NASDAQ:PETX) Shorted Shares Increased 6.12% After Market Selling - Consumer Eagle (NASDAQ:PETX) - July 18 at 6:54 PM logoIs $18 Price Target Attainable For Aratana Therapeutics, Inc. (NASDAQ:PETX)? - Investor Newswire (NASDAQ:PETX) - July 18 at 6:54 PM
News IconShares Moving Down on the Week: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Engelwood Daily (NASDAQ:PETX) - July 17 at 10:58 AM logoAratana Therapeutics, Inc. (NASDAQ:PETX) Quarterly Accounts Payable At $6.38 Millions - (NASDAQ:PETX) - July 16 at 6:17 PM
News IconAnalyst Target and Average Rating Watch: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Press Telegraph (NASDAQ:PETX) - July 16 at 10:02 AM logoWeakness in Aratana Shares An 'Excellent' Entry Point (NASDAQ:PETX) - July 15 at 5:48 PM
News IconIs Selling Aratana Therapeutics Inc Here a Winning Strategy? - Consumer Eagle (NASDAQ:PETX) - July 15 at 11:50 AM logoAratana Therapeutics : Appoints Chief Operating Officer (NASDAQ:PETX) - July 14 at 10:23 AM logoAratana Therapeutics to Report Second Quarter 2016 Financial Results (NASDAQ:PETX) - July 13 at 4:05 PM


Aratana Therapeutics (NASDAQ:PETX) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff